| Literature DB >> 1335196 |
Abstract
Since its development in 1974 the Oka strain live attenuated varicella vaccine has been tested in healthy and immunocompromised adults and children. Its safety and efficacy have been established and it is now licensed for general use in Japan and Korea, and for immunocompromised patients in several other countries. Possibilities for the future include its use to prevent zoster in the elderly, its incorporation in a multivalent vaccine and its use as a vehicle to express foreign genes in recombinant vaccines.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1335196 DOI： 10.1016/0264-410x(92)90109-w
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641